Triple-negative breast cancer (TNBC) is a type of breast cancer that does not have three commonly targeted receptors: estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2). Because these receptors are absent, treatments that target estrogen, progesterone, or HER2 are generally not effective against TNBC. TNBC can behave differently from other breast cancer subtypes and may require a combination of chemotherapy, immunotherapy, surgery, radiation, and targeted treatment depending on the stage and molecular characteristics of the cancer
What Is Triple-Negative Breast Cancer?
Breast cancer cells can contain receptors that influence how the cells grow.
The three markers used to define triple-negative breast cancer are:
- Estrogen receptor
- Progesterone receptor
- HER2
In TNBC, testing shows that the cancer cells lack significant levels of all three.
The term "triple-negative" describes the tumor's receptor status rather than the severity or stage of the cancer. TNBC can be diagnosed at different stages, and treatment depends heavily on the extent of disease.
Common Symptoms
Symptoms can resemble those of other types of breast cancer.
Possible signs include:
- A lump in the breast
- Change in breast size or shape
- Skin changes over the breast
- Nipple changes
- Nipple discharge
- Swelling
- Persistent breast discomfort
- A lump or swelling in the underarm area
Some breast cancers do not cause noticeable symptoms during the early stages and may be identified through screening.
How Is Triple-Negative Breast Cancer Diagnosed?
Diagnosis generally involves imaging and a biopsy.
Mammogram
A mammogram uses X-rays to produce images of breast tissue and may identify an abnormal area.
Ultrasound
Breast ultrasound can help distinguish fluid-filled areas from solid masses and can provide additional information about a suspicious finding.
Breast MRI
MRI may be recommended in certain situations to evaluate the extent of disease or assess additional areas of breast tissue.
Biopsy
A biopsy removes tissue from the suspicious area for examination by a pathologist.
The tissue can be tested for estrogen receptors, progesterone receptors, and HER2 to determine whether the cancer is triple-negative.
Staging
Once TNBC is diagnosed, additional testing may be used to determine the stage.
Staging considers factors such as:
- Tumor size
- Lymph-node involvement
- Spread to other parts of the body
- Biological characteristics of the tumor
Early-stage TNBC is confined to the breast or nearby lymph nodes, while metastatic disease has spread to distant organs.
Staging helps determine the most appropriate treatment strategy.
Treatment for Early-Stage TNBC
Treatment for early-stage TNBC often involves multiple approaches.
Chemotherapy
Chemotherapy is an important treatment for many people with TNBC because hormone therapy and HER2-targeted treatments are not appropriate for tumors without those receptors.
Chemotherapy may be given before surgery, after surgery, or in both settings depending on the clinical situation.
Immunotherapy
Immunotherapy has become an important treatment approach for certain patients with early-stage and advanced TNBC.
Pembrolizumab, an immune checkpoint inhibitor, may be used in combination with chemotherapy for selected patients with high-risk early-stage TNBC and may continue after surgery as part of the treatment plan.
Eligibility depends on factors such as disease stage and treatment protocol.
Surgery
Surgery can remove the breast tumor and may involve either breast-conserving surgery or mastectomy.
Lymph nodes may also be evaluated to determine whether cancer has spread beyond the breast.
Radiation Therapy
Radiation therapy may be recommended after breast-conserving surgery and in selected patients after mastectomy.
The purpose is to reduce the risk of cancer returning in the treated area.
Treatment for Metastatic TNBC
When TNBC spreads to distant parts of the body, treatment generally focuses on controlling the cancer, relieving symptoms, maintaining quality of life, and extending survival.
Treatment can include:
- Chemotherapy
- Immunotherapy
- Targeted therapy
- Antibody-drug conjugates
- Clinical trials
The specific treatment depends on previous therapies and the molecular characteristics of the cancer.
Targeted Treatment
Although TNBC lacks ER, PR, and HER2 receptors, some tumors contain other molecular features that can be targeted.
For example, patients with inherited or tumor-related BRCA mutations may be candidates for PARP inhibitors in appropriate clinical settings.
Another targeted approach is antibody-drug conjugate therapy. Sacituzumab govitecan is an example used for certain patients with advanced or metastatic TNBC.
Genetic Testing
Genetic counseling and testing can be important for people diagnosed with TNBC, particularly at younger ages or when there is a strong family history of breast or ovarian cancer.
Testing can identify inherited mutations such as changes in the BRCA1 or BRCA2 genes.
Results may have implications for:
- Treatment decisions
- Cancer-risk assessment
- Surgical planning
- Family members
Why TNBC Can Be Challenging to Treat
Because TNBC does not rely on estrogen, progesterone, or HER2 signaling in the same way as other breast cancers, several commonly used breast cancer treatments are not effective against it.
TNBC can also grow and spread more quickly than some other breast cancer subtypes. However, prognosis varies considerably based on stage, tumor biology, treatment response, and other individual factors.
Recurrence Risk
The risk of recurrence depends on multiple factors, including the original tumor size, lymph-node involvement, tumor biology, and response to treatment.
Recurrence can occur locally in the breast or chest area or in distant organs.
Regular follow-up appointments allow the healthcare team to monitor recovery and address new symptoms.
Clinical Trials
Clinical research continues to investigate new approaches for TNBC.
Areas of research include:
- New immunotherapy combinations
- Antibody-drug conjugates
- Targeted therapies
- Personalized treatment strategies
- New approaches for preventing recurrence
- Treatments for metastatic disease
Clinical trials can provide access to treatments that are not yet widely used in standard care.
Living With Triple-Negative Breast Cancer
Treatment can affect physical and emotional well-being.
Common concerns may include:
- Fatigue
- Hair loss
- Nausea
- Changes in appetite
- Sleep difficulties
- Anxiety
- Emotional stress
Support may come from family members, cancer-support organizations, oncology social workers, counselors, nutrition professionals, and the medical team.
Follow-Up Care
After treatment, follow-up care may include regular medical appointments and monitoring for recurrence or treatment-related effects.
Follow-up can also address:
- Breast health
- Medication effects
- Bone health when relevant
- Heart health after certain treatments
- Emotional well-being
- Genetic counseling
- Rehabilitation needs
The exact schedule depends on the treatment history and individual circumstances.
When to Seek Medical Evaluation
A new breast lump, persistent breast or nipple changes, unexplained swelling, or unusual nipple discharge should be evaluated by a healthcare professional.
A breast change does not automatically mean cancer, but prompt assessment can help determine the cause.
Conclusion
Triple-negative breast cancer is defined by the absence of estrogen receptors, progesterone receptors, and excess HER2. Because hormone therapy and HER2-targeted therapy are generally not effective for TNBC, treatment often relies on chemotherapy, immunotherapy, surgery, radiation, and selected targeted treatments.